Blood cancers

FISH testing to be funded for first line ibrutinib in CLL patients

Medicare funding for FISH testing for del(17p) has been recommended for all people with chronic lymphoid leukaemia (CLL) or small lymphocytic lymphoma (SLL), regardless of treatment line, so they can access first-line ibrutinib on the PBS. The genetic testing is already funded to allow second line treatment in people with relapsed or refractory CLL, and ...

Already a member?

Login to keep reading.

© 2021 the limbic